West Pharmaceutical (NYSE: WST) General Counsel plans departure by year-end 2025

Rhea-AI Filing Summary

West Pharmaceutical Services reported a leadership change in its legal organization. Kimberly Banks MacKay, Senior Vice President, General Counsel, and Corporate Secretary, will be leaving the company following a transition period. The company and Ms. MacKay plan to determine an appropriate transition that will end no later than December 31, 2025, to support a smooth handover of responsibilities. Until her departure, she will continue in her current role overseeing legal and corporate secretary duties. The company publicly thanked her for her service and contributions and expressed well wishes for her future endeavors.

Insights

Corporate governance analyst

West Pharmaceutical announces planned year-end departure of its General Counsel with a structured transition period.

The company disclosed that Senior Vice President, General Counsel, and Corporate Secretary Kimberly Banks MacKay will leave after a transition that concludes no later than December 31, 2025. She will maintain her current responsibilities until she departs, which helps preserve continuity for legal, compliance, and board-related functions during the transition.

The filing does not indicate any disruption to operations, and the planned timeline suggests an orderly handover rather than an abrupt change. Future disclosures may identify her successor or any related changes in governance structure, which can provide additional clarity on long-term leadership stability in the legal function.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0000105770false00001057702025-09-112025-09-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) – September 11, 2025

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania

1-8036

23-1210010

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

530 Herman O. West Drive, Exton, PA

19341-1147

(Address of principal executive offices)

(Zip Code)

 Registrant’s telephone number, including area code: 610-594-2900

Not Applicable

(Former name or address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol			Name of each exchange on which registered
Common Stock, par value $0.25 per share			WST			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

1

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Today, September 11, 2025, West Pharmaceutical Services, Inc. (the “Company”) announced that Kimberly Banks MacKay, Senior Vice President, General Counsel, and Corporate Secretary, will be leaving the Company. The Company and Ms. MacKay have agreed to discuss an appropriate transition period which will end no later than December 31, 2025, to ensure continuity and a smooth and orderly transition of responsibilities. Ms. MacKay will continue her current duties until she leaves the Company. The Company extends its gratitude to Ms. MacKay for her exemplary service and contributions during her tenure and wishes her success in her future endeavors.

Item 9.01 Financial Statements and Exhibits.

(d)			Exhibit No.			Description
			104			The cover page from the Company’s Current Report on Form 8-K, dated September 11, 2025, formatted in Inline XBRL.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 11, 2025			WEST PHARMACEUTICAL SERVICES, INC.
By:			/s/ Chad R. Winters
			Chad R. Winters
			Vice President, Finance & Chief Accounting Officer

3

EXHIBIT INDEX

Exhibit No.						Description
104						The cover page from the Company’s Current Report on Form 8-K, dated September 11, 2025, formatted in Inline XBRL.

4

FAQ

What leadership change did West Pharmaceutical Services (WST) disclose?

West Pharmaceutical Services disclosed that Kimberly Banks MacKay, its Senior Vice President, General Counsel, and Corporate Secretary, will be leaving the company following a transition period.

What is the transition timeline for West Pharmaceutical’s General Counsel departure?

The company and Kimberly Banks MacKay agreed to a transition period that will end no later than December 31, 2025, during which she will support an orderly handover of responsibilities.

Will Kimberly Banks MacKay continue her duties at West Pharmaceutical during the transition?

Yes. The filing states that Ms. MacKay will continue her current duties as Senior Vice President, General Counsel, and Corporate Secretary until she leaves the company.

Did West Pharmaceutical Services comment on Kimberly Banks MacKay’s tenure?

Yes. The company expressed gratitude for her exemplary service and contributions during her tenure and extended best wishes for her future endeavors.

Does the filing state when the departure of West Pharmaceutical’s General Counsel was announced?

Yes. The company indicated that the departure was announced on September 11, 2025, the same date as the report’s earliest event.